You have read all your free articles, to continue reading subscribe to read the rest of this content.
The launch of Pixelgen Technologies follows the close of an approximate 6 million USD seed round, led by Navigare Ventures. The founding will support the commercialization next year of the company's Molecular Pixelation technology for spatial analyses of cell surface proteins in 3D. "We are piAlready a subscriber Login You…
Immunicum has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for ilixadencel. Ilixadencel is a cell-based, off-the-shelf immune primer, for the treatment of Soft Tissue Sarcoma (STS). The designation recognizes results from the Phase I/II clinical trial inAlready a subscriber Login You have read all…
BerGenBio has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for bemcentinib in combination with an anti-PD-(L)1 agent as treatment for patients with STK11 altered advanced/metastatic NSCLC patients without actionable mutations. The Fast Track designAlready a subscriber Login You have read all your free…
UK's Sygnature Discovery will collaborate with Swedish biotech company Pelago Bioscience to provide target engagement assays with Pelago’s patented Cellular Thermal Shift Assay (CETSA) method. Pelago’s CETSA method enables measurements to be made within cellular systems. For the first time reAlready a subscriber Login You have read all your free…
